Details of the Drug Combination

General Information of Drug Combination (ID: DCVUTS0)

Drug Combination Name
Carglumic acid Acetazolamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Carglumic acid   DMCY0TI Acetazolamide   DM1AF5U
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 21.54
Bliss Independence Score: 21.54
Loewe Additivity Score: 36.48
LHighest Single Agent (HSA) Score: 36.48

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Carglumic acid
Disease Entry ICD 11 Status REF
Acute hyperammonaemia 5C50.A Approved [2]
Carglumic acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Carbamoyl-phosphate synthetase I (CPS1) TT42M75 CPSM_HUMAN Activator [5]
------------------------------------------------------------------------------------
Indication(s) of Acetazolamide
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [3]
Altitude sickness N.A. Approved [3]
Edema MG29 Approved [3]
Glaucoma/ocular hypertension 9C61 Approved [4]
Acetazolamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Acetazolamide Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Carbonic anhydrase 12 (CA12) OT6WNFU8 CAH12_HUMAN Decreases Activity [8]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Decreases Activity [9]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Decreases Activity [8]
Aquaporin-1 (AQP1) OTX5MYX9 AQP1_HUMAN Decreases Expression [10]
Rho GTPase-activating protein 45 (ARHGAP45) OTL86FEQ HMHA1_HUMAN Affects Expression [11]
Parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) OTQF5ZAK PTH1R_HUMAN Increases ADR [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7458).
3 Acetazolamide FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6792).
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Tamm-Horsfall protein accumulation in glomeruli during acetazolamide-induced acute renal failure. Am J Nephrol. 1989;9(1):56-7. doi: 10.1159/000167936.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011 Oct 13;54(19):6905-18.
9 Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action. Int J Clin Pharmacol Ther. 2001 Jun;39(6):265-70.
10 [Effect of inhibiting aquaporin-1 on proliferation and apoptosis of the Hep-2 cell]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Nov;20(21):988-91.
11 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.